Abstract：Objective: To investigate the effects of different doses of sildenafil on the cardiac function and serum CRP and MMP-9 levels in the treatment of neonatal persistent pulmonary hypertension. Methods: The clinical data of 125 neonates with persistent pulmonary hypertension were selected for retrospective analysis. The selection time was from February 2018 to April 2020, and they were divided according to the therapeutic dose of sildenafil into group A (0.5 mg, n= 42), group B (with 1.0 mg, n=42), group C (with 2.0 mg, n=41). The three groups were compared for C-reactive protein (CRP), matrix metalloproteinase-2 (MMP-9), N-terminal brain natriuretic peptide precursor (NT-pro BNP), right ventricular ejection fraction (RVEF), E value, A value, E/A, partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2), pulmonary artery systolic pressure (SPAP), and adverse events (nausea, vomiting, transient hypotension). Results: Repeated-measures ANOVA showed statistically significant (P<0.05) differences in time points, between-group differences and between-group interactions for CRP, NT-pro BNP, PaO2, PaCO2, SPAP, and E/A in the three groups; statistically significant (P<0.05) differences in time points and between-group interactions for MMP-9, RVEF, and E values in the three groups, while between-group differences were not statistically significant (P>0.05); the difference between time points of A values in the three groups was statistically significant (P<0.05), while the difference between groups and the interaction between time points and groups was not statistically significant (P>0.05). A two-by-two comparison showed that the differences in CRP, MMP-9, NT-pro BNP, RVEF, E, A, E/A, CRP, MMP-9 and NT-pro BNP were higher in groups B and C than in group A (P<0.05). Conclusion: Sildenafil at 1.0mg was effective in treating persistent pulmonary hypertension in neonates, improving cardiac function and reducing CRP and MMP-9 expression.
张维娜, 丁传刚, 赵丽芬, 李丽, 张曼军. 不同剂量西地那非治疗新生儿持续性肺动脉高压对患者心功能及血清CRP和MMP-9水平的影响[J]. 河北医学, 2022, 28(5): 867-872.
ZHANG Weina, DING Chuangang, ZHAO Lifen, et al. Effect of Different Doses of Sildenafil on Cardiac Function and Serum CRP and MMP-9 Levels in Neonates with Persistent Pulmonary Hypertension. HeBei Med, 2022, 28(5): 867-872.
[1] 马爱闻,徐继扬,陈俊,等.N末端B型钠尿肽原及心肌肌钙蛋白I对慢性阻塞性肺疾病合并肺动脉高压患者病情的评估价值[J].实用临床医药杂志,2020,24(7):16~19. [2] 高宁,杨梅,吴娜.血清HMGB1、BNP表达与新生儿持续性肺动脉高压的相关性研究[J].现代中西医结合杂志,2020,29(23):2551~2555. [3] Chikkabyrappa S M,Critser P,Roane J,et al.Tripartite assessment of right ventricular systolic function in persistent pulmonary hypertension of the newborn[J].Pediatr Cardiol,2020,41(6):1206~1211. [4] 中华医学会儿科学分会新生儿学组,《中华儿科杂志》编辑委员会.新生儿肺动脉高压诊治专家共识[J].中华儿科杂志,2017,55(3):163~168. [5] 朱梦茹,万彩红.高频振荡通气与西地那非联合治疗新生儿持续性肺动脉高压的临床效果[J].中国药物与临床,2021,21(12):2138~2140. [6] 才让卓玛,赵旭,薛林燕.TDI-Tei指数在高海拔地区肺动脉高压患者右心功能评价中的应用[J].河北医学,2018,24(6):927~931. [7] 杨海娟,许泽辉,张梦华.HFOV叠加CMV联合西地那非、注射用牛肺表面活性剂治疗重度PPHN的效果[J].河北医科大学学报,2020,41(3):315~318. [8] 张靖宇,曾利,王翠,等.血清BNP、VEGF、TGF-β1水平变化在新生儿持续性肺动脉高压病情评估中的临床意义[J].中华全科医学,2020,18(1):7~9,44. [9] Liu X,Mei M,Chen X,et al.Identification of genetic factors underlying persistent pulmonary hypertension of newborns in a cohort of Chinese neonates[J].Respir Res,2019,20(1):20(1):174. [10] 卢国琇,张娜娜,韦金苗.西地那非联合肺表面活性物质治疗新生儿肺动脉高压的疗效与安全性评价[J].临床肺科杂志,2020,25(10):1578~1581. [11] Ye L F,Yong F,Qiang S,et al.Management of persistent pulmonary hypertension in newborns with ECMO support:a single center's experience[J].World Pediatr,2019,15(1):100~103. [12] 万静,王新花,陈晓燕,等.大剂量西地那非治疗新生儿持续性肺动脉高压疗效和安全性的Meta-分析[J].药物评价研究,2020,43(6):1160~1166. [13] 窦蕾,张慧,李洁,等.不同剂量西地那非联合肺泡表面活性物质治疗新生儿持续性肺动脉高压的临床疗效观察[J].中国妇幼保健,2019,34(6):1280~1282.
2022, Vol. 28 
冀公网安备13080202000677号